| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702677 | Urologic Oncology: Seminars and Original Investigations | 2017 | 9 Pages |
Abstract
In this review, we systematically evaluate preclinical research and clinical trials that address resistance to the primary RCC therapies, including anti-angiogenesis agents, mTOR inhibitors, and immunotherapies. As clear cell RCC is the most common adult kidney cancer and has been the focus of most studies, it will be the focus of this review.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Peter J. M.D., Kathryn E. M.D., Ph.D., W. Kimryn M.D., Ph.D., Scott M. M.D.,